FARXIGA significantly reduced the risk of cardiovascular death or
https://www.astrazeneca-us.com/media/press-releases/2022/farxiga-significantly-reduced-the-risk-of-cardiovascular-death-or-worsening-of-heart-failure-in-patients-with-mildly-reduced-or-preserved-ejection-fraction-in-deliver-phase-III-trial.html
webAug 27, 2022 · FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial. PUBLISHED 27 August 2022. Results presented at European Society of Cardiology Congress 2022, and published in New England Journal of Medicine.
DA: 60 PA: 35 MOZ Rank: 26